We are delighted that Seda Pharmaceutical Development Services has been identified as ‘One to Watch’ in Alantra‘s Pharma Fast 50, published today.

The 2021 Alantra Pharma Fast 50 ranking is the fifth annual edition of this unique analysis of the UK’s fastest-growing, privately-owned pharmaceutical businesses according to their revenue growth over the past two years (the businesses must have reported revenues of more than £2m in the first year of assessment to be included).  Seda has been named alongside PostEra as ‘Ones to Watch’, a category introduced last year which identified businesses that do not yet meet all the criteria to make the main listing but which are “too exciting to omit”.

We are delighted to have been recognised for our exciting potential as a fast-growing, privately owned business and our unique contribution to the sector in terms of our “integrated mix of deep pharmaceutical development and clinical pharmacology knowledge”. Please read the full report, including comments from Seda CEO Paul Stott, here:  Alantra Pharma Fast 50 – 2021

Just five years after launch, our team’s choice to step outside big pharma and deliver expertise to a range of clients is paying off. Seda is growing rapidly, despite having devoted relatively little resource to business development, depending instead on referrals and recommendation.

The ranking also features on the front cover of the March Edition of PharmaTimes Magazine, the UK’s leading pharmaceutical magazine.